Quick Answer
Bicara Therapeutics Inc. reported R&D Expense of $63.60 million for fiscal year 2024.
Bicara Therapeutics Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $63.60M | +107.8% |
| 2023 | $30.60M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $33.00M | +107.5% | +33.1% |
| June 30, 2025 | $24.80M | +57.0% | -27.7% |
| March 31, 2025 | $34.30M | +185.8% | +115.7% |
| September 30, 2024 | $15.90M | +130.4% | +0.6% |
| June 30, 2024 | $15.80M | — | +31.7% |
| March 31, 2024 | $12.00M | — | +73.9% |
| September 30, 2023 | $6.90M | — | — |
- Bicara Therapeutics Inc. showed an increase of +107.8% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2024 period, Bicara Therapeutics Inc.’s r&d expense has grown by 107.8% (from $30.60 million to $63.60 million).
- The most recent figure is from Bicara Therapeutics Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 27, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: